• Je něco špatně v tomto záznamu ?

Precise determination of primary cytogenetic abnormalities provides added value for stratification of chronic lymphocytic leukemia patients

P. Dvorak, D. Lysak, P. Vohradska, I. Subrt

. 2019 ; 66 (1) : 128-139. [pub] 20180809

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034876

Cytogenetic analysis has become a standard procedure in the management of newly diagnosed chronic lymphocytic leukemia patients. Prognostic information is reported based on the presence of certain abnormalities and karyotype complexity after conventional karyotyping and/or fluorescence in situ hybridization (FISH). The information on cytogenetic abnormalities occurring in isolation is robust; however, the performance of patients with two or more cytogenetic abnormalities is heterogeneous and information is scarce. This retrospective study analyzed whether information on the precise determination of primary cytogenetic abnormalities can have some added value in terms of risk stratification in chronic lymphocytic leukemia (CLL) patients. The study cohort was 121 patients without the need to start treatment for CLL immediately after diagnosis but had completed initial cytogenetic analysis. Results from conventional karyotyping after stimulation of CLL cells and FISH analysis were combined. Risk stratification based purely on the determination of primary cytogenetic abnormalities was effective in CLL patients, with comparable results in stratification based on the presence of certain abnormalities and karyotype complexity. It is recommended that information on suspected primary abnormalities is included in cytogenetic reports, especially in patients with two or more abnormalities, because this can provide valuable additional information.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034876
003      
CZ-PrNML
005      
20191011133734.0
007      
ta
008      
191007s2019 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2018_180201N71 $2 doi
035    __
$a (PubMed)30509088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Dvořák, Pavel $7 _AN047353 $u Institute of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Institute of Medical Genetics, Faculty of Medicine in Pilsen, University Hospital Pilsen, Pilsen, Czech Republic
245    10
$a Precise determination of primary cytogenetic abnormalities provides added value for stratification of chronic lymphocytic leukemia patients / $c P. Dvorak, D. Lysak, P. Vohradska, I. Subrt
520    9_
$a Cytogenetic analysis has become a standard procedure in the management of newly diagnosed chronic lymphocytic leukemia patients. Prognostic information is reported based on the presence of certain abnormalities and karyotype complexity after conventional karyotyping and/or fluorescence in situ hybridization (FISH). The information on cytogenetic abnormalities occurring in isolation is robust; however, the performance of patients with two or more cytogenetic abnormalities is heterogeneous and information is scarce. This retrospective study analyzed whether information on the precise determination of primary cytogenetic abnormalities can have some added value in terms of risk stratification in chronic lymphocytic leukemia (CLL) patients. The study cohort was 121 patients without the need to start treatment for CLL immediately after diagnosis but had completed initial cytogenetic analysis. Results from conventional karyotyping after stimulation of CLL cells and FISH analysis were combined. Risk stratification based purely on the determination of primary cytogenetic abnormalities was effective in CLL patients, with comparable results in stratification based on the presence of certain abnormalities and karyotype complexity. It is recommended that information on suspected primary abnormalities is included in cytogenetic reports, especially in patients with two or more abnormalities, because this can provide valuable additional information.
650    12
$a chromozomální aberace $7 D002869
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a karyotypizace $7 D007621
650    _2
$a chronická lymfatická leukemie $x diagnóza $x genetika $7 D015451
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a hodnocení rizik $7 D018570
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lysák, Daniel $7 xx0105598 $u Department of Hematology and Oncology, Faculty of Medicine in Pilsen, University Hospital Pilsen, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Vohradská, Petra, $d 1964- $7 xx0106097 $u Institute of Medical Genetics, Faculty of Medicine in Pilsen, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Šubrt, Ivan, $d 1960- $7 xx0106759 $u Institute of Medical Genetics, Faculty of Medicine in Pilsen, University Hospital Pilsen, Pilsen, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 66, č. 1 (2019), s. 128-139
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30509088 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y p $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011134154 $b ABA008
999    __
$a ok $b bmc $g 1451536 $s 1073426
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 66 $c 1 $d 128-139 $e 20180809 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$b NLK118 $a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace